Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1. Impact of Moderate Aerobic Training on Physical Capacities of Hypertensive Obese Elderly. (PubMed)

Impact of Moderate Aerobic Training on Physical Capacities of Hypertensive Obese Elderly. The association of old age and chronic conditions, such as hypertension and obesity, can lead to larger decreases in the physical capacities of elderly, compared with their healthy counterparts. Physical exercise has been demonstrated to be efficient in postponing this phenomenon, mainly strength training. However, little is known about the effect of aerobic training on this condition. The aim of this work (...) was to investigate the impact of 12 weeks of moderate-intensity aerobic training on the physical capacities of hypertensive obese older women. Aerobic power, lower limb muscle power, upper limb muscle strength, endurance, and flexibility of 19 hypertensive obese elders were evaluated. Afterward, patients were blindly randomized into control group (CG) and exercise group (EG). EG underwent three sessions/week of 60 min of moderate-intensity aerobic training, during 12 weeks. EG showed increases in VO2max compared

2019 Gerontology & geriatric medicine Controlled trial quality: uncertain

2. Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy

Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy Inflammation is an important driver of hypertension. Periodontitis is a chronic inflammatory disease, which could provide a mechanism for pro-hypertensive immune activation, but evidence of a causal relationship in humans is scarce. We aimed to investigate the nature of the association between periodontitis and hypertension.We (...) on the effects of treatment of periodontitis on BP. One hundred and one hypertensive patients with moderate/severe periodontitis were randomized to intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n = 50) or control periodontal treatment (CPT; supragingival scaling; n = 51) with mean ambulatory 24-h (ABPM) systolic BP (SBP) as primary outcome. Intensive periodontal treatment improved periodontal status at 2 months, compared to CPT. This was accompanied by a substantial

2019 EvidenceUpdates

3. Endothelin receptor antagonists for pulmonary arterial hypertension

Endothelin receptor antagonists for pulmonary arterial hypertension '); } else { document.write(' '); } ACE | Endothelin receptor antagonists for treating pulmonary arterial hypertension Search > > Endothelin receptor antagonists for treating pulmonary arterial hypertension - Endothelin receptor antagonists for treating pulmonary arterial hypertension Published on 2 September 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 (...) mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: Idiopathic PAH; Heritable or familial PAH; PAH associated with connective tissue disease; Anorexigen-induced PAH; or PAH associated with HIV infection. Subsidy status Ambrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. MAF assistance

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

4. Therapeutic-induced hypertension in patients with noncardioembolic acute stroke

Therapeutic-induced hypertension in patients with noncardioembolic acute stroke To evaluate the safety and efficacy of induced hypertension in patients with acute ischemic stroke.In this multicenter randomized clinical trial, patients with acute noncardioembolic ischemic stroke within 24 hours of onset who were ineligible for revascularization therapy and those with progressive stroke during hospitalization were randomly assigned (1:1) to the control and intervention groups. In the intervention (...) patients were included in the intervention and control groups, respectively. After adjustment for age and initial stroke severity, induced hypertension increased the occurrence of the primary (odds ratio 2.49, 95% confidence interval [CI] 1.25-4.96, p = 0.010) and secondary (odds ratio 2.97, 95% CI 1.32-6.68, p = 0.009) efficacy endpoints. Sixty-seven (88.2%) patients of the intervention group exhibited improvements in NIHSS scores of ≥2 points during induced hypertension (mean SBP 179·7 ± 19.1 mm Hg

2019 EvidenceUpdates

5. In patients taking a beta blocker for uncomplicated hypertension, what is the best way to taper it off?

In patients taking a beta blocker for uncomplicated hypertension, what is the best way to taper it off? Chiefs’ Inquiry Corner 11/4/19 – Clinical Correlations Search Chiefs’ Inquiry Corner 11/4/19 November 4, 2019 2 min read Beta blockers (BBs) have fallen out of favor as first-line, or even second-line, treatment options for hypertension. And as patients’ medical regimens gradually drop BBs, concerns may arise about the rebound phenomenon we learn in medical school. With chronic beta blocker

2019 Clinical Correlations

6. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial The Hygia Chronotherapy Trial, conducted within the clinical primary care setting, was designed to test whether bedtime in comparison to usual upon awakening hypertension therapy exerts better cardiovascular disease (CVD) risk reduction.In this multicentre, controlled, prospective endpoint trial, 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) were assigned (1:1 (...) ) to ingest the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory blood pressure (ABP) monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke). Patients of the bedtime, compared

2019 EvidenceUpdates

7. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. (PubMed)

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Hypertension is the leading cause of cardiovascular disease globally. Despite proven benefits, hypertension control is poor. We hypothesised that a comprehensive approach to lowering blood pressure and other risk factors, informed by detailed analysis of local barriers, would be superior to usual care in individuals with poorly controlled or newly diagnosed (...) hypertension. We tested whether a model of care involving non-physician health workers (NPHWs), primary care physicians, family, and the provision of effective medications, could substantially reduce cardiovascular disease risk.HOPE 4 was an open, community-based, cluster-randomised controlled trial involving 1371 individuals with new or poorly controlled hypertension from 30 communities (defined as townships) in Colombia and Malaysia. 16 communities were randomly assigned to control (usual care, n=727

2019 Lancet

8. Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. (PubMed)

Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. Persistent pulmonary hypertension of the newborn (PPHN) is a disease entity that describes a physiology in which there is persistence of increased pulmonary arterial pressure. PPHN is characterised by failure to adapt to a functional postnatal circulation with a fall in pulmonary vascular resistance. PPHN is responsible for impairment in oxygenation and significant neonatal mortality and morbidity

2019 Cochrane

9. Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: July 24, 2019 Project Number: RB1358-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What is the cost-effectiveness of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What are the guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety

Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety | CADTH.ca Find the information you need Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Last updated: January 24, 2019 Project Number: RB1300-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the evidence associated with the development (...) of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain? Key Message No relevant literature was identified regarding the evidence associated with the development of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain. Files Rapid Response Summary of Abstracts Published : January 24, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension

Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension British Society of Gastroenterology Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension. Contents Guidelines development group 3 Abstract 4 Executive summary of recommendations 4 Research recommendations: 12 Patient summary 14 Introduction 17 Guideline development 17 Assessing the quality of guidelines: The AGREE II instrument 17 History of TIPSS (...) 19 Indications for TIPSS 22 TIPSS for Variceal Bleeding 22 TIPSS for ascites, hepatic hydrothorax and hepatorenal syndrome 27 TIPSS for ascites 27 TIPSS for hepatic hydrothorax 30 TIPSS for hepatorenal syndrome (HRS) 31 TIPSS and Budd Chiari Syndrome 32 TIPSS prior to non-hepatic surgery in patients with portal hypertension (prophylactic TIPSS) 34 TIPSS and idiopathic non-cirrhotic portal hypertension (INCPH) 36 TIPSS in portal vein thrombosis 37 Patient selection 39 Hepatic encephalopathy 39 Pre

2019 British Society of Gastroenterology

12. Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update

Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update CTS GUIDELINES AND POSITION PAPERS Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update Doug Helmersen a , Steeve Provencher b , Andrew M. Hirsch c , Anne Van Dam d , Carole Dennie e , Marc De Perrot f , Lisa Mielniczuk g , Naushad Hirani a , George Chandy h , John Swiston i , Dale Lien j , Nick H. Kim k (...) , Marion Delcroix l , and Sanjay Mehta m a Pulmonary Hypertension Program, Division of Respiratory Medicine, Peter Lougheed Centre, University of Calgary, Calgary, Alberta, Canada; b Institut Universitaire de Cardiologie et de Pneumologie de Qu ebec, Universit e de Laval, Quebec, Quebec, Canada; c Centre for Pulmonary Vascular Disease, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada; d Canadian Thoracic Society, Ottawa, Ontario, Canada; e Thoracic and Cardiac

2019 Canadian Thoracic Society

13. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. (PubMed)

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although (...) effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or low-resource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy.In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible

2019 Lancet Controlled trial quality: predicted high

14. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. (PubMed)

Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. The hypertensive disorders of pregnancy include pre-eclampsia, gestational hypertension, chronic hypertension, and undefined hypertension. Pre-eclampsia is considerably more prevalent in low-income than in high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half (...) to be inadequate. This is an update of a review first published in 2017.To determine the effect of calcium supplementation, given before or early in pregnancy and for at least the first half of pregnancy, on pre-eclampsia and other hypertensive disorders, maternal morbidity and mortality, and fetal and neonatal outcomes.We searched the Cochrane Pregnancy and Childbirth Trials Register (31 July 2018), PubMed (13 July 2018), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP; 31

2019 Cochrane

15. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. (PubMed)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use (...) of spironolactone in patients with chronic kidney disease and resistant hypertension.In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to ≤45 mL/min per 1·73 m2) and uncontrolled resistant hypertension from 62 outpatient centres in ten countries (Bulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA). Patients meeting all

2019 Lancet

16. Morbidity of Persistent Pulmonary Hypertension of the Newborn in the First Year of Life

Morbidity of Persistent Pulmonary Hypertension of the Newborn in the First Year of Life To assess postdischarge mortality and morbidity in infants diagnosed with different etiologies and severities of persistent pulmonary hypertension of the newborn (PPHN), and to identify risk factors for these adverse clinical outcomes.This was a population-based study using an administrative dataset linking birth and death certificates, hospital discharge and readmissions records from 2005 to 2012

2019 EvidenceUpdates

17. Hypertension in adults: diagnosis and management

Hypertension in adults: diagnosis and management Hypertension in adults: diagnosis and Hypertension in adults: diagnosis and management management NICE guideline Published: 28 August 2019 www.nice.org.uk/guidance/ng136 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in adults: diagnosis and management (NG136) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 40Contents Contents Overview 4 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

18. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. (PubMed)

Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Antihypertensive medicines are effective in reducing adverse cardiovascular events. Our aim was to compare hypertension awareness, treatment, and control, and how they have changed over time, in high-income countries.We used data from people aged 40-79 years who participated in 123 national health examination surveys from 1976 to 2017 (...) in 12 high-income countries: Australia, Canada, Finland, Germany, Ireland, Italy, Japan, New Zealand, South Korea, Spain, the UK, and the USA. We calculated the proportion of participants with hypertension, which was defined as systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 90 mm Hg or more, or being on pharmacological treatment for hypertension, who were aware of their condition, who were treated, and whose hypertension was controlled (ie, lower than 140/90 mm Hg).Data

2019 Lancet

19. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. (PubMed)

The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Evidence from nationally representative studies in low-income and middle-income countries (LMICs) on where in the hypertension care continuum patients are lost to care is sparse. This information, however, is essential for effective targeting of interventions by health services and monitoring progress in improving (...) hypertension care. We aimed to determine the cascade of hypertension care in 44 LMICs-and its variation between countries and population groups-by dividing the progression in the care process, from need of care to successful treatment, into discrete stages and measuring the losses at each stage.In this cross-sectional study, we pooled individual-level population-based data from 44 LMICs. We first searched for nationally representative datasets from the WHO Stepwise Approach to Surveillance (STEPS) from

2019 Lancet

20. Evaluation and Treatment of Asymptomatic Hypertension

Evaluation and Treatment of Asymptomatic Hypertension Evaluation and Treatment of Asymptomatic Hypertension | Emergency Medicine | Washington University in St. Louis Open Menu Back Close Menu Search for: Loading... Welcome Our Team Sections Education Alumni Research ECRC Journal Club Events Jermyn Lectures Open Search Vignette You are working an evening shift in The Deuce when your next patient is roomed—a 53-year-old African American woman whose chief complaint is elevated blood pressure. She (...) for articles publised between 1/1/2010 to 3/13/2019 (i.e. since the previous journal club) using the terms (hypertens* OR elevated blood pressure) AND “emergency department”. . This strategy yielded articles from which the four most relevant articles were chosen. Articles Article 1: Article 2: . Article 3: . Article 4: Bottom Line Hypertension, which , represents not only a significant public health burden, but also places a significant burden on emergency departments. In the US, 2006 and 2013, rising from

2019 Washington University Emergency Medicine Journal Club